SPEXIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0756 CHF | -2.83% |
|
-2.83% | +84.39% |
| 05-01 | SIX Swiss Exchange Approves Delay in Spexis' FY23 Annual Report Publication | MT |
| 04-17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
| Sales 2021 | 331 363.43 28.61K | Sales 2022 | 1.48M 1.62M 128M | Capitalization | 19.96M 21.92M 1.73B |
|---|---|---|---|---|---|
| Net income 2021 | -11M -12.08M -951M | Net income 2022 | -18M -19.76M -1.56B | EV / Sales 2021 * | - |
| Net cash position 2021 | 6.23M 6.84M 539M | Net Debt 2022 | 4.23M 4.65M 366M | EV / Sales 2022 | 16.4 x |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-1.07
x | Employees | 28 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 50.23% |
More Fundamentals
* Assessed data
More news
Latest transcript on Spexis AG
More press releases
| 1 day | -2.83% | ||
| 1 week | -2.83% | ||
| Current month | +28.57% | ||
| 1 month | +37.45% | ||
| 3 months | -62.20% | ||
| 6 months | +117.24% | ||
| Current year | +84.39% |
1 week
0.06
0.08
1 month
0.050.08
Current year
0.041.06
1 year
0.011.06
3 years
0.012.20
5 years
0.012.20
10 years
0.012.20
| Managers | Title | Age | Since |
|---|---|---|---|
Jeffrey Wager
CEO | Chief Executive Officer | 62 | 29/12/21 |
Martin Jakobovic
DFI | Director of Finance/CFO | - | - |
Stephan Wehselau
COO | Chief Operating Officer | 55 | 29/12/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dan Hartman
BRD | Director/Board Member | 62 | 29/12/21 |
Dennis Ausiello
BRD | Director/Board Member | 78 | 29/12/21 |
Kuno Sommer
BRD | Director/Board Member | 68 | 31/08/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/05/24 | 0.0756 | -2.83% | 66,021 |
| 16/05/24 | 0.0778 | +12.75% | 78,544 |
| 15/05/24 | 0.069 | +4.55% | 149,533 |
| 14/05/24 | 0.066 | -15.17% | 206,976 |
Delayed Quote Swiss Exchange, May 17, 2024 at 04:30 pm
More quotes
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Sector
Pharmaceuticals
Calendar
04/09/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +84.39% | 5.64M | |
| -2.78% | 90.45B | |
| +3.95% | 41.45B | |
| -10.51% | 33.57B | |
| +60.58% | 25.73B | |
| -20.09% | 14.73B | |
| -8.92% | 12.82B | |
| -11.46% | 11.7B | |
| -43.05% | 11.44B | |
| +5.17% | 8.79B |
- Stock Market
- Equities
- SPEX Stock
